NovoCure Ltd announced that it will be completing the study of Novo TTF by October 2012.
Novo TTF is a portable device intended for the cancer treatment using Tumor Treating Fields(TTFields). It is developed for continuous home use by patients with a recurrent or progressive glioblastoma tumor. The device disrupts cancer cell proliferation and tumor growth by creating low intensity, intermediate frequency, alternating electric fields in the region of a tumor. These electric fields exert forces on the dividing cancer cells that prevent tumor growth. The NovoTTF-100A is a non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box. The technician places the electrodes on the outside of the scalp. The electrodes generally resemble bandages with wires attached. The electrodes connect to a portable TTField-generating box running off a battery. The device is lightweight (approximately 6 lbs) and fits neatly into a dedicated carrying case that will be provided to the patient.
The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrodes.
The 283 patient study is currently recruiting participants. The official title of the study is “A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM”.